The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting

Supportive Care in Cancer

Volumn 21, Issue 8, 2013, Pages 2335-2339

  Mercadante, Sebastiano ^a,b   Porzio, Giampiero ^c   Aielli, Federica ^c   Averna, Lucilla ^c   Ficorella, Corrado ^c   Casuccio, Alessandra ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Breakthrough episodic pain; Cancer pain; Fentanyl buccal tablet; Home care; Opioids

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; BREAKTHROUGH CANCER PAIN; BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOME CARE; HUMAN; MALE; OPEN STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 84879913938     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1799-2     Document Type: Article

References (27)

1. Aronoff G, Brennan M, Pritchard D, Ginsberg B (2005) Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med 6:305-314
2. Caraceni A, Martini C, Zecca E, Portenoy RK et al (2004) Working group of an IASP task force on cancer pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18:177-183
3. Corli O, Pizzuto M (2011) Capire e trattare il brealkthrough cancer pain. Center for the Evaluation and Research on Pain. CIC edizioni internazonali 9-25
4. Davies A, Vriens J, Kennett A, McTeggart (2008) An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage 35:406-411
5. Davies AD, Dickman A, Reid C, Stevens A, Zeppetella G (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331-338
6. Davies A, Zeppetella G, Andersen S et al (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15:756-763
7. Hagen NA, Fisher K, Victorino C, Farrar JT (2007) A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 10:47-55
8. Hanks GW, De Conno F, Cherny N et al (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587-593
9. Kleeberg UR, Filbet M, Zeppetella G (2011) Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Pain Pract 11:185-190
10. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24:425-443
11. Mercadante S (2012) Pharmacotherapy for breakthrough cancer pain. Drugs 72(2):181-190
12. Mercadante S, Ferrera P, Adile C, Casuccio A (2011) Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage 42:464-469
13. Mercadante S (2011) The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 80:460-465
14. Mercadante S, Gatti A, Porzio G, Lo Presti C, Aielli F, Adile C, Casuccio A (2012) Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin 28:963-968
15. Mercadante S (2009) Breakthrough pain: on the road again. Eur J Pain 13:329-430
16. Mercadante S (2010) Intravenous morphine for management of cancer pain. Lancet Oncol 11:484-489
17. Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A (2004) Safety and effectiveness of intravenous morphine for episodic-breakthrough pain, using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 27:352-359
18. Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, Mangione S (2008) Intravenous morphine for episodic-breakthrough pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 35:307-313
19. Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G (2007) Transmucosal fentanyl vs. intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 96:1828-1833
20. Mercadante S, Villari P, Ferrera P, Mangione S, Casuccio A (2010) The use of opioids for breakthrough pain in an acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain 26:306-309
21. Mercadante S, Ferrera P, Adile C, Casuccio A (2011) Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage 42:464-469
22. Mercadante S, Villari P, Casuccio A (2011) An Italian survey on the attitudes in treating breakthrough cancer pain in hospice. Support Care Cancer 19:979-983
23. Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence, and characteristics. Pain 41:273-281
24. Portenoy RK, Payne D, Jacobson P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129-134
25. Slatkin NE, Xie F, Messina J, Segal TJ (2007) Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 5:327-234
26. Zeppetella GB (2008) Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 35:563-567
27. Zeppetella G, Messina J, Xie F, Slatkin NE (2010) Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Pract 10:287-293